SCHEMBL791807

SCHEMBL791807

O=c1[nH]c2cccc(N3CCN(CCCCNS(=O)(=O)c4cc5ccccc5s4)CC3)c2o1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 19/20 0.57
HTR2A P28223 13/20 0.57
HTR7 P34969 11/20 0.57
HTR6 P50406 11/20 0.57
MCHR1 Q99705 1/20 0.49
HTR1A P08908 7/20 0.47
DRD3 P35462 3/20 0.47
DRD1 P21728 2/20 0.47
DRD4 P21917 2/20 0.47
HTR2C P28335 2/20 0.47
ADRA1A P35348 2/20 0.47
ADRA2C P18825 1/20 0.47
HRH1 P35367 1/20 0.47
KCNH2 Q12809 1/20 0.47
SLC6A4 P31645 2/20 0.46
ADRA1D P25100 1/20 0.44
ADRA1B P35368 1/20 0.44
HTR2B P41595 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL792936 0.97 DRD2 (0.57) DRD2HTR2AHTR7HTR6MCHR1
SCHEMBL793126 0.91 DRD2 (0.53) DRD2HTR2AHTR7HTR6MCHR1
SCHEMBL791038 0.88 DRD2 (0.51) DRD2HTR2AHTR7HTR6MCHR1
SCHEMBL792808 0.82 DRD2 (0.62) DRD2HTR2AHTR7HTR6HTR1A
SCHEMBL15064338 0.80 DRD2 (0.58) DRD2HTR2AHTR7HTR6MCHR1
SCHEMBL793124 0.80 DRD2 (0.56) DRD2HTR2AHTR7MCHR1HTR1A
SCHEMBL791204 0.79 DRD2 (0.54) DRD2HTR2AHTR7MCHR1HTR1A
SCHEMBL791832 0.79 DRD2 (0.60) DRD2HTR2AHTR7HTR6HTR1A
SCHEMBL793457 0.79 HTR1A (0.58) DRD2HTR2AHTR7HTR6MCHR1
SCHEMBL791619 0.79 HTR7 (0.59) DRD2HTR2AHTR7HTR6HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9120767-B2 Arylosulfonamides for the treatment of CNS diseases ADAMED SP. Z.O.O. (PL) 2015-09-01 US disclosed
US-20140336200-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z O.O. (PL) 2014-11-13 US disclosed
US-8822517-B2 Arylosulfonamides for the treatment of CNS diseases ADAMED SP. Z O.O. (PL) 2014-09-02 US disclosed
EP-2616440-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES Adamed sp. z o.o. (PL) 2013-07-24 EP disclosed
US-20130172365-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z.O.O. (PL) 2013-07-04 US disclosed
WO-2012035123-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z O.O. (PL) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336200-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ARSA, PMP22, STS DRD2 3216/4885HTR2A 1150/4885HTR7 1419/4885
US-20130172365-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ARSA, PMP22, STS DRD2 3216/4885HTR2A 1150/4885HTR7 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.